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Recent correspondence in thcse columns' has highlighted problems for some 'direct kit' methods related to marked under recovery of 17-hydroxyprogesterone ( I 7 OHP) from specimens distributed by UKEQAS. Discussion centred around the validity of such methods for the measurement of endogenous 17 OHP concentrations in adult serum. Readers should be aware that these problems are compounded if the assays are applied to specimens obtained from neonates.
It has been well documented that in the neonatal period maturation of the adrenal gland causes a changing pattern in both serum and urine steroid profiles. This change is related to the involution, soon after birth, of the fetal adrenal gland (responsible, in part, for production of ocstrogen precursors in utero) causing dramatic reduction of delta-5 steroids. In infants born prematurely this involution is dclayed and high concentrations of delta-5 urinary steroid metabolites are present for as long as 6 months.' Direct measurcment of 17-OHP is being used incrcasingly in neonatal screening programmes for congenital adrenal hyperplasia.' It is well recognized that thcse direct 17-OHP results are much higher than the corresponding results following solvent extraction and that this discrepancy is most marked for premature infants4 Previously we suggested that this may be related to the presence of large amounts of a delta-5 steroid sulphate (1 7-hydroxypregnenolone sulphatc) which cross-reacts with most antisera for 17-hydroxyprogesterone. This suspicion has recently been confirmed by isolation of the interfering factor from neonatal serum and identification by gas chromatography/mass spectrometry.' It is of relevance to the present correspondence that the 'Coat-a-Count' direct 17-OHP method (Diagnostic Products Corporation) has been identified as suffering from interference of this nature and that the antibody employed in early versions of this kit showed marked cross-reactiv-ity with 17-hydroxypregneneolone sulphate in formal tests." We understand that a change of antibody in this kit has reduced, though not eliminated, the problem.
It is important that these problems are recognized by clinical biochemists as inappropriate use of direct kits in neonates may result in misdiagnosis. We recommend that in all circumstances other than screening a solvent extraction step be included in any 17-OHP analysis on an infant aged less than 6 months of age. Furthermore, extremely careful validation of any direct immunoassay used for measuring neonatal steroid samples is required before routine use.
